Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Mar 18, 2024 10:01pm
91 Views
Post# 35939575

RE:RPINVESTOR1

RE:RPINVESTOR1Great  deal  for  Andrew.  If  they  sold  something for  $70  million  - that would be $1  per  shareholder.

Under the  new deal  the  shareholder would split 5.6  million  or  $0.08  per  share   and Andrew  gets  his  8 cents per share plus the other 92%   Now  if he has  about $4  million in it   All he wants to do  is sell  something  for say $5  million  to break even.   So this  deal  arrived at with a special committee of the  directors  is designed to get Andrew his money back  but really no one else.

I  think at this point we would be better if someone else  with  some asset vended it into the Replicel shell  and  tried to run it up.  Can;t really be much  worse a deal  for  outside shareholders

With this imbalance seems Andrew  has a chance to get his money  back  (MAYBE)  but no one else does.  Just sad that it has taken all these years to get here.   They should have tried to sell assets before to benefit everyone,  not just the few!!!

GLTA
<< Previous
Bullboard Posts
Next >>